<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070784</url>
  </required_header>
  <id_info>
    <org_study_id>D589DC00008</org_study_id>
    <nct_id>NCT01070784</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan</brief_title>
  <official_title>An Open-label Phase III, Multi-centre 52-week , Parallel-group Study Evaluating the Safety and Efficacy of Symbicort Turbuhaler 320/9 Twice Daily Compared With Standard Treatment in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Symbicort Turbuhaler
      compared to standard COPD treatment during one year in Japanese patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Erythrocytes</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Mean change from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Haemoglobin</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Leucocytes</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Platelet Count</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Eosinophils</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Basophils</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Lymphocytes</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Monocytes</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Neutrophils</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Creatinine</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Sodium</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Potassium</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S- Calcium</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Albumin</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs- Sitting Systolic Blood Pressure(SBP)</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs- Sitting Diastolic Blood Pressure(DBP)</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs- Pulse Rate</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables - Heart Rate</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables - QT Interval</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables - QTcB Interval</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables - QTcF Interval</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables - RR Interval</measure>
    <time_frame>Baseline and 52 week after</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening</measure>
    <time_frame>Daily during run-in period and daily during 52-week randomization treatment</time_frame>
    <description>There are 5 alternatives (scored 0 to 4, 0= no awakening and 4 =did not sleep at all). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness</measure>
    <time_frame>Daily during run-in period and daily during 52-week randomization treatment</time_frame>
    <description>There are 5 alternatives (scored 0 to 4, 0= unaware of any difficulty and 4 =almost constant, present even when resting). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough</measure>
    <time_frame>Daily during run-in period and daily during 52-week randomization treatment</time_frame>
    <description>There are 5 alternatives (scored 0 to 4, 0= unaware of coughing, 4= never free of cough or need to cough). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic</measure>
    <time_frame>Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization</time_frame>
    <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic</measure>
    <time_frame>Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization</time_frame>
    <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD Exacerbation</measure>
    <time_frame>Daily during 52-week randomization treatment</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD Exacerbations Over the Study Treatment Period</measure>
    <time_frame>Daily during 52-week randomization treatment</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use</measure>
    <time_frame>Daily during 52-week randomization treatment</time_frame>
    <description>The change from run-in period and daily during 52-week randomization treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
    <description>The change from run-in period and daily during 52-week randomization treatment average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow (PEF) Measured at Home</measure>
    <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
    <description>The change from Run-in period average to 52-week randomization Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening Peak Expiratory Flow (PEF) Measured at Home</measure>
    <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
    <description>The change from Run-in period average to 52-week randomization Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning FEV1 Measured by the Subjects at Home</measure>
    <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
    <description>The change from run-in period and daily during 52-week randomization treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening FEV1 Measured by the Subjects at Home</measure>
    <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
    <description>The change from run-in period and daily during 52-week randomization treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbuhaler (Budesonide/formoterol)</intervention_name>
    <description>2 x 160/4.5 microgram, inhalation, bid, 52 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Symbicort Turbuhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: any available COPD treatment; investigator to decide</intervention_name>
    <description>According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A current clinical diagnosis of COPD according to the guidelines (GOLD, JPS)

          -  Documented COPD symptoms for more than 2 years

          -  Pre-bronchodilator FEV1≦50% of predicted normal value, and post-bronchodilator
             FEV1/FVC＜70%

        Exclusion Criteria:

          -  History and/or current clinical diagnosis of asthma and atopic diseases such as
             allergic rhinitis

          -  Subjects with significant or unstable ischemic heart disease, arrhythmia,
             cardiomyopathy, heart failure, uncontrolled hypertension as defined by the
             investigator, or any other relevant cardiovascular disorder as judged by the
             investigator

          -  COPD exacerbation during the run-in period or within 4 weeks prior to registration,
             requiring hospitalization and/or treatment with systemic steroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Andersson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca, R&amp;D, Lund, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyota</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itami</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koshi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shibata</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=397&amp;filename=CSR-D589DC00008.pdf</url>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <results_first_submitted>October 8, 2012</results_first_submitted>
  <results_first_submitted_qc>October 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2013</results_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symbicort</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>COPD</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant entered the study on 28 January 2010, and the last participant completed the study on 24 October 2011. A total of 328 participants were enrolled at 60 centres in Japan, and 260 participants who fulfilled the randomisation criteria were randomised.</recruitment_details>
      <pre_assignment_details>The study starts with an enrolment visit, Visit 1 prior to any other study-related activity. At Visit 2, the lung function will be measured to assess the eligibility of the patients. Subjects who fulfil all eligibility criteria will begin the 2-week run-in period.During the period, the previous treatment will be continued to record the baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort Turbuhaler</title>
          <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
        </group>
        <group group_id="P2">
          <title>COPD Standard Therapy</title>
          <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort Turbuhaler</title>
          <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
        </group>
        <group group_id="B2">
          <title>COPD Standard Therapy</title>
          <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.1" lower_limit="40" upper_limit="87"/>
                    <measurement group_id="B2" value="71.5" lower_limit="54" upper_limit="85"/>
                    <measurement group_id="B3" value="70.8" lower_limit="40" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Erythrocytes</title>
        <description>Mean change from Baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Erythrocytes</title>
          <description>Mean change from Baseline</description>
          <units>*10000/μl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="23.9"/>
                    <measurement group_id="O2" value="-0.1" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Haemoglobin</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Haemoglobin</title>
          <description>Change from baseline</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.74"/>
                    <measurement group_id="O2" value="-0.05" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Leucocytes</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Leucocytes</title>
          <description>Change from baseline</description>
          <units>/microliter(mcl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.8" spread="1704.0"/>
                    <measurement group_id="O2" value="-184.8" spread="1238.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Platelet Count</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Platelet Count</title>
          <description>Change from baseline</description>
          <units>*10000/μl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="3.03"/>
                    <measurement group_id="O2" value="0.12" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Eosinophils</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Eosinophils</title>
          <description>Change from baseline</description>
          <units>percentage of Eosinophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="2.68"/>
                    <measurement group_id="O2" value="0.14" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Basophils</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Basophils</title>
          <description>Change from baseline</description>
          <units>percentage of Basophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.37"/>
                    <measurement group_id="O2" value="-0.06" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Lymphocytes</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Lymphocytes</title>
          <description>Change from baseline</description>
          <units>percentage of Lymphocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.47" spread="6.56"/>
                    <measurement group_id="O2" value="-3.24" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Monocytes</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Monocytes</title>
          <description>Change from baseline</description>
          <units>percentage of Monocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="1.41"/>
                    <measurement group_id="O2" value="-0.03" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Neutrophils</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Neutrophils</title>
          <description>Change from baseline</description>
          <units>percentage of Neutrophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="7.16"/>
                    <measurement group_id="O2" value="2.92" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase</title>
          <description>Change from baseline</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="7.6"/>
                    <measurement group_id="O2" value="1.5" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase</title>
          <description>Change from baseline</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="7.6"/>
                    <measurement group_id="O2" value="1.1" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)</title>
          <description>Change from baseline</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="38.4"/>
                    <measurement group_id="O2" value="8.2" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Creatinine</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Creatinine</title>
          <description>Change from baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.106"/>
                    <measurement group_id="O2" value="-0.017" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin</title>
          <description>Change from baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.25"/>
                    <measurement group_id="O2" value="0.00" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Sodium</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Sodium</title>
          <description>Change from baseline</description>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.0"/>
                    <measurement group_id="O2" value="-0.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Potassium</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Potassium</title>
          <description>Change from baseline</description>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.34"/>
                    <measurement group_id="O2" value="-0.08" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S- Calcium</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S- Calcium</title>
          <description>Change from baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.34"/>
                    <measurement group_id="O2" value="0.01" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Albumin</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Albumin</title>
          <description>Change from baseline</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.24"/>
                    <measurement group_id="O2" value="0.04" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total</title>
          <description>Change from baseline</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.35"/>
                    <measurement group_id="O2" value="0.02" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein</title>
          <description>Change from baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.243" spread="1.291"/>
                    <measurement group_id="O2" value="0.224" spread="1.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen</title>
          <description>Change from baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="4.09"/>
                    <measurement group_id="O2" value="-0.64" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs- Sitting Systolic Blood Pressure(SBP)</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs- Sitting Systolic Blood Pressure(SBP)</title>
          <description>Change from baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="16.2"/>
                    <measurement group_id="O2" value="-3.2" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs- Sitting Diastolic Blood Pressure(DBP)</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs- Sitting Diastolic Blood Pressure(DBP)</title>
          <description>Change from baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="11.2"/>
                    <measurement group_id="O2" value="-1.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs- Pulse Rate</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs- Pulse Rate</title>
          <description>Change from baseline</description>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="11.1"/>
                    <measurement group_id="O2" value="3.1" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables - Heart Rate</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables - Heart Rate</title>
          <description>Change from baseline</description>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="11.4"/>
                    <measurement group_id="O2" value="3.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables - QT Interval</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables - QT Interval</title>
          <description>Change from baseline</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="23.1"/>
                    <measurement group_id="O2" value="-7.5" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables - QTcB Interval</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables - QTcB Interval</title>
          <description>Change from baseline</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="20.9"/>
                    <measurement group_id="O2" value="2.4" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables - QTcF Interval</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables - QTcF Interval</title>
          <description>Change from baseline</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="16.3"/>
                    <measurement group_id="O2" value="-1.1" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables - RR Interval</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and 52 week after</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables - RR Interval</title>
          <description>Change from baseline</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.9" spread="121.4"/>
                    <measurement group_id="O2" value="-43.8" spread="115.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening</title>
        <description>There are 5 alternatives (scored 0 to 4, 0= no awakening and 4 =did not sleep at all). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening</title>
          <description>There are 5 alternatives (scored 0 to 4, 0= no awakening and 4 =did not sleep at all). The change from Run-in period average to Treatment period average for each treatment group</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness</title>
        <description>There are 5 alternatives (scored 0 to 4, 0= unaware of any difficulty and 4 =almost constant, present even when resting). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness</title>
          <description>There are 5 alternatives (scored 0 to 4, 0= unaware of any difficulty and 4 =almost constant, present even when resting). The change from Run-in period average to Treatment period average for each treatment group</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.7"/>
                    <measurement group_id="O2" value="-0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough</title>
        <description>There are 5 alternatives (scored 0 to 4, 0= unaware of coughing, 4= never free of cough or need to cough). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough</title>
          <description>There are 5 alternatives (scored 0 to 4, 0= unaware of coughing, 4= never free of cough or need to cough). The change from Run-in period average to Treatment period average for each treatment group</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.7"/>
                    <measurement group_id="O2" value="-0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic</title>
        <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.</description>
        <time_frame>Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic</title>
          <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.</description>
          <units>percentage of Baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.25" lower_limit="60.8" upper_limit="182.9"/>
                    <measurement group_id="O2" value="98.43" lower_limit="35.8" upper_limit="168.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic</title>
        <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.</description>
        <time_frame>Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic</title>
          <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group. Ratio is being reported as a percentage in this Measure.</description>
          <units>percentage of Baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.51" lower_limit="77.8" upper_limit="141.5"/>
                    <measurement group_id="O2" value="100.04" lower_limit="67.6" upper_limit="158.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First COPD Exacerbation</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.</description>
        <time_frame>Daily during 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First COPD Exacerbation</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD Exacerbations Over the Study Treatment Period</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment</description>
        <time_frame>Daily during 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations Over the Study Treatment Period</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment</description>
          <units>event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use</title>
        <description>The change from run-in period and daily during 52-week randomization treatment</description>
        <time_frame>Daily during 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use</title>
          <description>The change from run-in period and daily during 52-week randomization treatment</description>
          <units>innhalation/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.0"/>
                    <measurement group_id="O2" value="0.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life (HRQL) Based on the St. George’s Respiratory Questionnaire (SGRQ)</title>
        <description>The change from run-in period and daily during 52-week randomization treatment average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).</description>
        <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life (HRQL) Based on the St. George’s Respiratory Questionnaire (SGRQ)</title>
          <description>The change from run-in period and daily during 52-week randomization treatment average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="8.56"/>
                    <measurement group_id="O2" value="-0.42" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow (PEF) Measured at Home</title>
        <description>The change from Run-in period average to 52-week randomization Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (PEF) Measured at Home</title>
          <description>The change from Run-in period average to 52-week randomization Treatment period average for each treatment group</description>
          <units>Liter/minute(L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="31.8"/>
                    <measurement group_id="O2" value="5.7" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Peak Expiratory Flow (PEF) Measured at Home</title>
        <description>The change from Run-in period average to 52-week randomization Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Evening Peak Expiratory Flow (PEF) Measured at Home</title>
          <description>The change from Run-in period average to 52-week randomization Treatment period average for each treatment group</description>
          <units>Liter/minute(L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="30.0"/>
                    <measurement group_id="O2" value="5.2" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning FEV1 Measured by the Subjects at Home</title>
        <description>The change from run-in period and daily during 52-week randomization treatment</description>
        <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Morning FEV1 Measured by the Subjects at Home</title>
          <description>The change from run-in period and daily during 52-week randomization treatment</description>
          <units>Liter(L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" spread="0.147"/>
                    <measurement group_id="O2" value="0.006" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening FEV1 Measured by the Subjects at Home</title>
        <description>The change from run-in period and daily during 52-week randomization treatment</description>
        <time_frame>Daily during run-in period and daily 52-week randomization treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - COPD Standard Therapy</title>
            <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
          </group>
        </group_list>
        <measure>
          <title>Evening FEV1 Measured by the Subjects at Home</title>
          <description>The change from run-in period and daily during 52-week randomization treatment</description>
          <units>Liter(L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.142"/>
                    <measurement group_id="O2" value="0.010" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Symbicort Turbuhaler</title>
          <description>Symbicort Turbuhaler, 160/4.5 microgram(mcg), 2 inhalations twice daily</description>
        </group>
        <group group_id="E2">
          <title>COPD Standard Therapy</title>
          <description>Standard COPD treatment according to JRS guideline and GOLD guideline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis Obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Computerised Tomogram Thorax Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Synovial Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Optic Ischaemic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Angle Closure Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Heat Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Loss Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Gastric Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Laryngeal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Organising Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Chronic Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Goran Eckerwall, MSD</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

